Join the Inclisiran group to help and get support from people like you.
Inclisiran News
Novartis' Twice-Yearly Leqvio (inclisiran) Receives FDA Approval for New Indication Enabling First-Line Use
EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ – Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran), enabling its use as ...
US FDA Approves Expanded Indication for Leqvio (inclisiran) to Include Treatment of Adults with High LDL-C and Who Are At Increased Risk of Heart Disease
Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to...
FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C)
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and...
Further information
Related condition support groups
High Cholesterol - Familial Heterozygous, High Cholesterol